Abstract:Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor malignancies, including lung cancer and colorectal cancer (CRC). Epiregulin (EREG) is one of the EGFR ligands and is low expressed in most normal tissues. Elevated EREG in various cancers mainly activates EGFR signaling pathways and promotes cancer progression. Notably, a higher EREG expression level in CRC with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) is related to better efficacy of therapeutic treatment. By contrast, the resistance of anti-EGFR therapy in CRC was driven by low EREG expression, aberrant genetic mutation and signal pathway alterations. Additionally, EREG overexpression in non-small cell lung cancer (NSCLC) is anticipated to be a therapeutic target for EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, recent findings indicate that EREG derived from macrophages promotes NSCLC cell resistance to EGFR-TKI treatment. The emerging events of EREG-mediated tumor promotion signals are generated by autocrine and paracrine loops that arise from tumor epithelial cells, fibroblasts, and macrophages in the tumor microenvironment (TME). The TME is a crucial element for the development of various cancer types and drug resistance. The regulation of EREG/EGFR pathways depends on distinct oncogenic driver mutations and cell contexts that allows specific pharmacological targeting alone or combinational treatment for tailored therapy. Novel strategies targeting EREG/EGFR, tumor-associated macrophages, and alternative activation oncoproteins are under development or undergoing clinical trials. In this review, we summarize the clinical outcomes of EREG expression and the interaction of this ligand in the TME. The EREG/EGFR pathway may be a potential target and may be combined with other driver mutation targets to combat specific cancers.

EGFR Phosphorylation of DCBLD2 Recruits TRAF6 and Stimulates AKT-promoted Tumorigenesis

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Egf-Induced Erk Activation Promotes Ck2-Mediated Disassociation of Alpha-Catenin from Beta-Catenin and Transactivation of Beta-Catenin

EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer

Egf Potentiated Oncogenesis Requires A Tissue Transglutaminase-Dependent Signaling Pathway Leading To Src Activation

TRAF6 Regulates EGF-induced Cell Transformation and Cscc Malignant Phenotype Through CD147/EGFR

EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma

Abstract 1890: IKBKE is a Substrate of EGFR and a Therapeutic Target in NSCLCs with Activating Mutations of EGFR

Nerve Growth Factor (Ngf)-Trka Axis in Head and Neck Squamous Cell Carcinoma Triggers EMT and Confers Resistance to the EGFR Inhibitor Erlotinib.

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers

Novel Tyrosine Phosphorylation Targets of EGF Signaling and Gefitinib in Human Cancer Cells.

PDGFR‐β‐activated ACK1‐AKT Signaling Promotes Glioma Tumorigenesis

Tyrosine Phosphorylation Activates 6-Phosphogluconate Dehydrogenase and Promotes Tumor Growth and Radiation Resistance

Overexpression of TRAF4 promotes lung cancer growth and EGFR-dependent phosphorylation of ERK5

The Role of EREG/EGFR Pathway in Tumor Progression

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1

Tumor Necrosis Factor Receptor-associated Factor Family Protein 2 is a Key Mediator of the Epidermal Growth Factor-induced Ribosomal S6 Kinase 2/Camp-Responsive Element-binding Protein/Fos Protein Signaling Pathway*